- Home
- Publications
- Publication Search
- Publication Details
Title
CD19 as an attractive target for antibody-based therapy
Authors
Keywords
-
Journal
mAbs
Volume 4, Issue 5, Pages 571-577
Publisher
Informa UK Limited
Online
2012-08-15
DOI
10.4161/mabs.21338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract 4624: High affinity CD3 RECRUIT-TandAbs for T cell-mediated lysis of malignant CD19+B cells
- (2012) Uwe Reusch et al. CANCER RESEARCH
- The future of antibodies as cancer drugs
- (2012) Janice M. Reichert et al. DRUG DISCOVERY TODAY
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells
- (2012) S Rafiq et al. LEUKEMIA
- Abstract C164: Preclinical pharmacological characterization of GBR 401, a new monoclonal antibody directed against human CD19.
- (2012) S. Hou et al. MOLECULAR CANCER THERAPEUTICS
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia
- (2011) Giovanni Cazzaniga et al. BRITISH JOURNAL OF HAEMATOLOGY
- A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
- (2011) Elizabeth Ward et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia
- (2011) John Schindler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses
- (2011) Michael Kalos CANCER IMMUNOLOGY IMMUNOTHERAPY
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptors in Cancer Immuno-Gene Therapy: Current Status and Future Directions
- (2011) Leonardo Chicaybam et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus
- (2011) Holly M. Horton et al. JOURNAL OF IMMUNOLOGY
- Action of novel CD37 antibodies on chronic lymphocytic leukemia cells
- (2011) G Krause et al. LEUKEMIA
- Chimeric Antigen Receptor–Modified T Cells in CLL
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
- Rituximab for the Treatment of Non-Hodgkinʼs Lymphoma and Chronic Lymphocytic Leukaemia
- (2010) Fredrick Hagemeister DRUGS
- Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia
- (2010) Misato Kikuchi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
- (2010) R. Herbst et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
- (2009) H.-P. Gerber et al. BLOOD
- CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
- (2009) F. T. Awan et al. BLOOD
- A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
- (2009) Pina M. Cardarelli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
- (2009) A. M. Al-Katib et al. CLINICAL CANCER RESEARCH
- A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia
- (2009) Larry Herrera et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
- (2009) Daniel A. Vallera et al. LEUKEMIA RESEARCH
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- The impact of Fc engineering on an anti-CD19 antibody: increased Fc receptor affinity enhances B-cell clearing in nonhuman primates
- (2008) J. Zalevsky et al. BLOOD
- Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
- (2008) M. Amann et al. CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
- (2008) Sandrine d’Argouges et al. LEUKEMIA RESEARCH
- Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
- (2008) Seung Y. Chu et al. MOLECULAR IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search